tbuckley/cabot-search huggingface dataset:
Dynamics and Evolution of the Preleukemic Clone in Slow Onset Leukemias
Authors: Olga Zimmermannova, Ondrej Hrusak, Eva Fronkova, Marketa Kubricanova Zaliova, Ester Mejstrikova, Katerina Muzikova, Zuzana Zemanova, Eva Malinova, Jan Stary, Jan Zuna
Journal: Blood (2012)
BIOV-111 a European Phase II Trial of Clofarabine (Evoltra®) in Refractory and Relapsed Childhood Acute Lymphoblastic Leukemia.
Authors: Pamela Kearns, Gerard Michel, Brigitte Nelken, Simon Joel, Essam Al-Ghazaly, Auke Beishuizen, Valentino Conter, Helmut Gadner, Gunter Henze, Hazel Smith, Andre Baruchel, Vaskar Saha
Journal: Blood (2006)
Prognostic role of thymidylate synthase (TS) gene polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
Authors: K. Kawakami, F. Graziano, G. Watanabe, A. Ruzzo, D. Santini, V. Catalano, R. Bisonni, R. Ficarelli, S. Cascinu, M. Magnani
Journal: Journal of Clinical Oncology (2005)

4044 Background: Previous studies suggest that TS expression in tumor tissue is related with both sensitivity to 5-FU-based chemotherapy and patients’outcome. TS gene has polymorphic sequences in its untranslated region (UTR) which are associated with TS expression. Aim of this study is to evaluate prognostic role of the TS polymorphisms in gastric cancer patients treated with surgery and 5-FU-based adjuvant chemotherapy. Methods: Ninety patients with advanced gastric cancer who had undergone radical surgery and received 5-FU-based adjuvant chemotherapy were included in this study. All patients underwent a 44-months minimum follow-up time. Lymphocyte genomic DNA was extracted from peripheral blood samples of the patients. Genotypes of variable number of tandem repeat (VNTR) and G/C single nucleotide polymorphism (SNP) in the TS 5’-UTR and 6bp deletion polymorphism in the 3’-UTR were determined by PCR and PCR-RFLP. According to previous studies the VNTR and the SNP were combined and the genotypes were grouped as follows; 5’-high (3G/3G, 3G/3C, 2R/3G) and 5’-low (2R/2R, 2R/3C, 3C/3C). Genotypes in 3’-UTR were also classified as follows; 3’-high (ins6/ins6) and 3’-low (del6/ins6, del6/del6). Results: There were no significant relationships between clinico-pathologic features and each TS polymorphism. Ten patients were 5’-high/3’-high (100% relapse/death), 36 patients were 5’-high/3’-low (67% relapse/death, 33% disease-free), 19 patients were 5’-low/3’-high (58% relapse/death, 42% disease-free), 25 patients were 5’-low/3’-low (36% relapse/death, 64% disease-free). Patients with 5’-low/3’-low genotypes showed significantly better outcome than those with 5’-high/3’-low and 5’-high/3’-high genotypes in regard to both 3-year disease-free and overall survival rates. The presence of at least one high TS expression genotype showed independent adverse prognostic role in multivariate analysis. Conclusions: TS polymorphisms showed prognostic influence in the studied population of gastric cancer patients. Analysis of combined TS5’- and TS3’-UTR genotypes may be useful for improving adjuvant treatment strategies with tailored chemotherapy. No significant financial relationships to disclose.
S33 Physical activity intervention versus pulmonary rehabilitation in copd: the lively copd project
Authors: B O’Neill, OM O’Shea, SM McDonough, L McGarvey, I Bradbury, MA Arden, T Troosters, D Cosgrove, T McManus, TJ McDonnell, JM Bradley
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> The format of pulmonary rehabilitation (PR) may not meet the needs of all patients with COPD or lead to improved physical activity (PA) levels. Drop outs from PR can be high. A pedometer driven physical activity intervention (PAI) may offer patients an alternative method for increasing their PA. The aim of this study was to assess the feasibility of a 12 week clinician facilitated PAI versus PR in people with COPD. <h3>Methods</h3> The design was a multicenter-randomised, parallel-group, feasibility study. Patients with COPD referred for PR were included. Spirometry and demographics were recorded. The following were assessed at baseline, post-intervention and follow up (12 weeks): PA using an ActiGraph GT3X+ accelerometer, sealed Yamax Digiwalker pedometer and the International Physical Activity Questionnaire (IPAQ) (long form); exercise capacity (Incremental Shuttle Walk Test (ISWT)); COPD Assessment Test (CAT). Recruitment, retention and completion/rates were recorded. Descriptive statistics and mean differences were used to analyse the data. <h3>Results</h3> 50 patients (mean (SD) age 64 (8) years, 24M, FEV1 1.44 (0.63)) were recruited and randomised: PR n = 26, PAI n = 24. Of those screened 50/651, 13% were recruited. One participant randomised to the PAI started PR, a per protocol analysis was conducted; PR n = 27 and PAI n = 23. Completion of the PAI was 74% (17/23) and PR was 48% (13/27). Retention overall was 74% post-intervention (n = 18 PAI; n = 19 PR), and 66% at follow up (n = 15 PAI; n = 18 PR). There was a mean (95% confidence interval (CI)) change of 972 (−1080 to 3024) steps/day and 4 (−441 to 449) in the PAI and PR group respectively; results are found in Table 1. There were 4 minor adverse events (PAI n = 3 PR n = 1). <h3>Conclusions</h3> This study will inform a future large scale randomised control trial (RCT). The LIVELY PAI intervention appears to be feasible and safe within this preliminary study, and enhanced physical activity in people with COPD. While the results require confirmation in a fully powered RCT, the mean increase in step count is in line with a recently published minimally clinically important difference.<sup>1</sup> <h3>Reference</h3> Demeyer H, <i>et al</i>. The Minimal Important Difference in Physical Activity in Patients with COPD. <i>PLoS One</i>. 2016;<b>11</b>:0154587.
Platelet Engraftment (PE) in AML Patients Receiving HLA Matched Sibling Donor Allogeneic Bone Marrow Transplant (ABMT) Correlates with Inhibitory HLA Ligand Groups for Killer Immunoglobulin-Like Receptors (KIRs).
Authors: Ronald Sobecks, Edward J. Ball, Lisa Rybicki, Stacey Brown, Jaroslaw Maciejewski, Matt Kalaycio, Brad Pohlman, Elizabeth Kuczkowski, Julie Curtis, Brian Bolwell
Journal: Blood (2005)
Abstract 19936: Venous Thromboembolism Recurrence and Bleeding Risk Among Cancer Patients Using a Large Commercial Database
Authors: Cristina Masseria, Furaha Kariburyo, Jack Mardekian, Theodore C Lee, Yaniv Ravee, Hemant Phatak, Onur Baser, Melissa Hamilton, Lin Xie
Journal: Circulation (2015)

Objectives: To describe the role of anticoagulant use, active cancer and venous thromboembolism (VTE) type on bleeding risk and VTE recurrence among cancer patients diagnosed with VTE. Methods: A retrospective observational analysis of the Humedica database between 01JAN2008 and 31MARCH2014 was conducted including adult patients (aged &gt;18 years) with ≥2 VTE diagnosis claims (ICD-9-CM codes) in an outpatient setting or with one VTE diagnosis in an inpatient setting who had continuous health plan enrollment 6 months pre-index date. Active cancer patients were differentiated from cancer patients based on diagnosis codes during the baseline period. The incidence rate (in person-years) was calculated for major bleeding and VTE recurrence. Time-to-major bleeding and time-to-VTE recurrence were estimated using Kaplan-Meier curves; a Cox regression was applied to adjust for baseline demographic and clinical characteristics. Results: A total of 72,224 cancer patients were identified, which included 8,222 active cancer patients. More than 70% of cancer patients were prescribed anticoagulants. The incidence rate of VTE recurrence (24.7 vs. 14.3 per 100 person-years) and major bleeding events (31.2 vs. 15.9 per 100 person-years) was higher among active cancer patients than all VTE cancer patients. The use of combination parenteral and oral anticoagulant treatment (hazard ratio [HR]=1.30, p&lt;0.0001), active cancer (HR=1.10, p=0.0007) and having both pulmonary embolism (PE) and deep vein thrombosis (DVT) as prior diagnoses (HR=1.17, P&lt;0.0001) were significantly associated with an increased risk of major bleeding. Clinical predictors of VTE recurrence included active cancer (HR=1.35, p&lt;0.0001) and having both PE and DVT as prior diagnoses (HR=1.32, p&lt;0.0001). Patients treated with anticoagulants (HR=0.71, p&lt;0.0001) were at a lower risk of VTE recurrence. Discussion: Active cancer and having both PE and DVT as prior diagnoses were associated with increased VTE recurrence and bleeding risk. The bleeding risk was also highest among patients undergoing parenteral and oral anticoagulant therapy. However, anticoagulant treatment was shown to be associated with a lower risk of VTE recurrence.
Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome
Authors: Roos M. van der Vuurst de Vries, Julia Y. Mescheriakova, Tessel F. Runia, Naghmeh Jafari, Theodora A. M. Siepman, Rogier Q. Hintzen
Journal: JAMA Neurology (2017)

<h3>Importance</h3> There is a growing number of therapies that could be administered after the first symptom of central nervous system demyelination. These drugs can delay multiple sclerosis (MS) diagnosis and slow down future disability. However, treatment of patients with benign course may not be needed; therefore, there is a need for biomarkers to predict long-term prognosis in patients with clinically isolated syndrome (CIS). <h3>Objective</h3> To investigate whether the T-cell activation marker soluble CD27 (sCD27) measured in cerebrospinal fluid of patients at time of a first attack is associated with a subsequent diagnosis of MS and a higher relapse rate. <h3>Design, Setting, and Participants</h3> This prospective study included 77 patients with CIS between March 2002 and May 2015 in a tertiary referral center for multiple sclerosis, in collaboration with several regional hospitals. Patients with CIS underwent a lumbar puncture and magnetic resonance imaging scan within 6 months after first onset of symptoms. <h3>Main Outcomes and Measures</h3> Soluble CD27 levels were determined in cerebrospinal fluid using a commercially available enzyme-linked immunosorbent assay. Cox regression analyses was used to calculate univariate and multivariate hazard ratios for MS diagnosis. Association between sCD27 levels and relapse rate was assessed using a negative binomial regression model. <h3>Results</h3> Among 77 patients with CIS, 50 were female (79.5%), and mean (SD) age was 32.7 (7.4) years. Mean (SD) age in the control individuals was 33.4 (9.5) years, and 20 were female (66.7%).Patients with CIS had higher cerebrospinal fluid sCD27 levels than control individuals (geometric mean, 31.3 U/mL; 95% CI, 24.0-40.9 vs mean, 4.67 U/mL; 95% CI, 2.9-7.5;<i>P</i> &lt; .001). During a mean (SD) follow-up of 54.8 (35.1) months, 39 of 77 patients (50.6%) were diagnosed as having MS. In a model adjusted for magnetic resonance imaging and cerebrospinal fluid measurements, sCD27 levels were associated with a diagnosis of MS (hazard ratio, 2.4 per 100 U/mL increase in sCD27 levels; 95% CI, 1.27-4.53;<i>P</i> = .007). Additionally, patients with MS with high sCD27 levels (median, &gt;31.4 U/mL) at the time of CIS had a 5.5 times higher annualized relapse rate than patients with low sCD27 levels (annualized relapse rate, 0.06 vs 0.33;<i>P</i> = .02). <h3>Conclusions and Relevance</h3> Soluble CD27 in cerebrospinal fluid of patients with CIS was associated with MS diagnosis and a high relapse rate. Therefore, sCD27 is an activation molecule directly related to the immunopathology of the disease and is a potential clinical marker to help in treatment decisions after a first attack of suspected MS.
P3.02a-026 Crizotinib in Clinical Practice and in Clinical Trials - How Much the Results Differ?
Authors: Peter Berzinec, Lukas Plank, Juraj Mazal, Igor Andrasina, Andrea Cipkova, Robert Godal, Lucia Denkova, Maria Cerna, Gabriela Chowaniecova, Ivan Kudera, Iveta Kuliskova, Helena Kuzmova, Marian Martak, Zuzana Pribulova, Maria Reckova, Milada Vesela
Journal: Journal of Thoracic Oncology (2017)
OA07.02 Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis
Authors: Xing Wang, Nan Wu, Shi Yang, Chao Lv, Shaolei Li, Yuzhao Wang, Jia Wang, Lijian Zhang, Yue Yang
Journal: Journal of Thoracic Oncology (2017)
Generalizability in Pragmatic Trials
Authors: José A. Sacristán, Tatiana Dilla
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024
Authors: Julie R. Brahmer, Delvys Rodríguez-Abreu, Andrew G. Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Anne C. Deitz, Gregory M. Lubiniecki, Jin Zhang, Reshma Rangwala, Martin Reck
Journal: Journal of Thoracic Oncology (2017)
M12 TRPV1 polymorphism in chronic cough: no evidence for an effect on objective measurements of cough
Authors: RD Turner, E Bourne, CA Mein, SS Birring, SO Shaheen, GH Bothamley
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> The afferent receptor TRPV1 is implicated in the cough reflex. Several single nucleotide polymorphisms (SNPs) in <i>TRPV1</i> appear to be associated with symptoms of cough in the general population.<sup>1</sup> We investigated whether such SNPs are associated with the objective measures of cough reflex sensitivity and 24-hour cough frequency (CF24) in chronic cough. <h3>Methods</h3> Patients were recruited from a specialist cough clinic with cough &gt;2 months’ duration as the only or predominant symptom. Each underwent measurement of C5 (minimum concentration of capsaicin required to produce 5 coughs) and wore the Leicester Cough Monitor for 24 h. Saliva samples were taken to extract DNA and genotype six SNPs of <i>TRPV1</i>: rs161365, rs17706630, rs2277675, rs222741, rs150854 and rs224498. Mean values of C5 and CF24 were compared across genotypes and univariate linear regression was used to analyse the per minor allele associations with each outcome for each SNP, on the assumption their effects would be additive.<sup>1</sup> <h3>Results</h3> 57 patients were recruited with underlying diagnoses including unexplained chronic cough (n = 43), asthma (n = 7) and gastro-oesophageal reflux (n = 2). 42 (74%) were female, and median (IQR) age and duration of cough was 60 (54–66) years and 5 (3–12) months, respectively. Median (IQR) C5 was 7.8 (3.9–15.6) μM/L and cough frequency 399 (181–651) coughs/24 h. Genotype frequencies were as shown (Table). There was no evidence for an association between <i>TRPV1 </i>polymorphisms and C5 or CF24. This was the case regardless of diagnosis. <h3>Conclusion</h3> This small study did not provide support for a large effect of <i>TRPV1</i> polymorphism on cough frequency or cough reflex sensitivity in chronic cough. However, we lacked power to detect small/modest effects. <h3>Reference</h3> Smit, <i>et al</i>. <i>Respir Res</i> 2012;<b>13</b>:26.
P2.04-043 Squamous Cell Carcinoma Arising from the Pleura. An Interesting Case Report
Authors: Nektarios Alevizopoulos, Ioanna Sigala, Areti Dimitriadou, Theodoros Tegos, Vasili Edwin, Vasiliki Ntalapera, Nickie Loukas, Michael Vaslamatzis
Journal: Journal of Thoracic Oncology (2017)
A Silver Lining
Authors: Diya Kapila
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
P1.01-042 Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer
Authors: Matthew Schabath, Tapashi Dalvi, Hongyue Dai, Alan Crim, Anita Midha, Norah Shire, Jill Walker, Danielle Greenawalt, David Lawrence, James Rigas, Robert Brody, Danielle Potter, Naveen Kumar, Shane Huntsman, Jhanelle Gray
Journal: Journal of Thoracic Oncology (2017)
P2.02-047 Association of FDG PET, Complete Pathological Response and Overall Survival in Patients with Pancoast Tumors Treated with Trimodality Therapy
Authors: Sam Mcarthur, Kalhara Perera, Bibhusal Thapa, Marsali Newman, Tineke Fancourt, Sze Ting Lee, Thomas John, Adeline Lim, Salvatore Berlangieri, Andrew Scott, Gavin Davis, Simon Knight, Stephen Barnett
Journal: Journal of Thoracic Oncology (2017)
Advanced biliary access techniques: is the double-guidewire technique considered a “Wednesday’s child”?
Authors: Phonthep Angsuwatcharakon, Pradermchai Kongkam, Rungsun Rerknimitr
Journal: Endoscopy (2017)

Selective biliary cannulation is used as a gateway for therapeutic biliary endoscopy. The average success rate of biliary cannulation procedures using conventional cannulation techniques is 90 % (range 70.6 % – 98.9 %); on average, 10 % of the biliary cannulations performed can be considered to be difficult, requiring more advanced techniques to allow deep cannulation [1]. Currently, there are many advanced techniques available, including precut sphincterotomy, transpancreatic septotomy (TPS), the double-guidewire technique (DGT), and cannulation over a pancreatic stent [2].
P284 Identifying patients at risk of acute exacerbation of ipf using the cpi score
Authors: E Fraser, V St Noble, R Benamore, R Hoyles, LP Ho
Journal: Thorax (2016)

<h3>Introduction</h3> Disease course in IPF is punctuated by acute declines, often termed acute exacerbations of IPF (AEIPF) and portends to a mortality of 80% within 3 months. The cause of AEIPF is poorly understood; and there is currently no effective treatment. There is an urgent need to understand the causes and to characterise the parameters that identify patients at risk of AEIPF. Because lung function (DLCO and FVC) and CT imaging are the most accessible (potential) methods for identification of patients at risk of AEIPF, we question if these could be used to identify patient at risk of AEIPF. We explored the utility of the CPI<sup>1</sup> (composite physiological index) for this purpose. <h3>Methods</h3> Patients with IPF diagnosed by clinico-pathologic-radiological criteria, according to the 2011 ATS/ERS/JRS/ALAT guidelines, with definite or probable diagnosis of IPF were recruited over a one year period, and divided into stable (n = 12) and AEIPF (n = 8) groups. AEIPF was defined as: 1) deterioration in dyspnoea over 30 days or less 2) new airspace infiltrates on HRCT (with or without evidence of infection) 3) exclusion of pulmonary emboli and heart failure. Lung function (FVC and DLCO) and CPI at 12 months before recruitment and rate of change of FVC within these 12 months were determined. <h3>Results and discussion</h3> Patients with AE-IPF had a significantly higher CPI; (mean ± SD) – 62 ± 13 vs stable 45 ± 7; p = 0.001. In contrast, there was no significant difference in FVC levels between the two groups – 61 ± 4% predicted in AE-IPF group vs 72 ± 3% in stable; p = 0.07. CPI but not FVC or DLCO was worse 12 months prior to recruitment in the AEIPF group. Rate of loss in FVC in the year before AEIPF was not significantly different from those with stable disease <h3>Conclusions</h3> Early findings suggest that in contrast to DLCO and FVC, high CPI is associated with occurrence of AEIPF within a year. Rate of FVC loss did not correlate with AEIPF in this small study. CPI could be a more sensitive predictor for AEIPF than FVC and DLCO but larger numbers and a prospective study will be required to test this concept. <h3>Reference</h3> Wells AU. AJRCCM 2003.
Abstract 145: Glucose Depletion Is Essential For The Calorie-restriction-mediated Cardiac Angiogenesis Via Pka/ampk-dependent Autophagy.
Authors: Akio Monji, Yasuko K Bando, Morihiko Aoyama, Toko Mitsui, Haruya Kawase, Toyoaki Murohara
Journal: Circulation Research (2013)

Background: Caloric restriction (CR) promotes beneficial cardiovascular effects; however, its effects on cardiac angiogenesis remain unclear. We thus examined whether CR may modulate cardiac angiogenesis via activation of autophagy and seeked for the essential nutrient factor(s) that may be responsible for the CR-mediated angiogenesis. Methods: To confirm whether CR-induced angiogenic effects may be universally observed, we allocated 2 distinct heart failure models; #1 pressure overload (4 weeks) generated by transaortic constriction (TAC) and #2 diet-induced obesity (DIO) mice, as a model of diabetic cardiomyopathy. Male mice (14 w/o) were randomly allocated to a 4-week CR (TAC-CR and DIO-CR) and ad libitum (TAC-AL and DIO-AL). Cultured endothelial cells (ECs) were exposed to culture media of 1) ordinary composition, 2) glucose-depleted, 3) amino acid-depleted, and 4) serum-depleted condition. To visualize cardiac autophagic changes, GFP-LC3 mice were allocated to DIO and TAC treatment. Analyses for the changes in activities of autophagy (LC3-turnover assay and p62 level) and angiogenesis (tube formation and Akt/AMPK/eNOS activity) were evaluated. Results: Immunohistochemical analyses revealed that CR enhanced cardiac angiogenesis both in TAC and DIO mice. CR promoted increased in myocardial cyclic AMP concentration with concomitant PKA/AMPK/eNOS activation and the simultaneous increase in autophagic activity both in TAC and DIO hearts. Of note, cardiac Akt activity remains unchanged by CR. In vitro analysis revealed that glucose depletion, as well as forskolin (10 μM) and 8-bromo-cyclic AMP (1 mM), activated PKA/AMPK axis thereby facilitated angiogenesis and autophagy in ECs. The enhanced in vitro angiogenesis induced by glucose depletion and PKA enhancers was abrogated by autophagy inhibitor 3-MA treatment. PKA inhibitors (H89 and RP-cAMP) abrogated the increase in AMPK/eNOS phosphorylation levels induced by glucose depletion. Neither amino acid- nor serum-depletion had no effect on angiogenesis and autophagy. Conclusions: Glucose depletion is essential for the CR-mediated activation of cardiac angiogenesis and autophagy in a cAMP/PKA/AMPK-dependent fashion.